Novaminsulfon is a prescription drug that contains the active ingredient metamizole and may only be used on medical advice.

Novaminsulfon has an analgesic effect (analgesic), lowering fever (antipyretic) and antispasmodic (spasmolytic). Novaminsulfon is used for acute severe pain after injuries and operations, for cramp-like pain such as biliary and urinary tract colic, for tumor pain or comparable severe pain conditions. Novaminsulfon is also very effective in the case of a high fever that cannot be reduced by other measures.

At acute Pain and chronic In severe pain, Novaminsulfon is a potent pain reliever when other treatments cannot be used.

The active ingredient metamizole is controversial because of the possible undesirable effects and is rarely prescribed. The active ingredient in Novaminsulfon, however, has very good antipyretic and analgesic properties, which is why it is still popular in hospitals.

Novaminsulfon is often used as a reserve agent. This means that Novaminsulfon is used when other measures have not been successful.


Novaminsulfone are usually available as tablets, film-coated tablets, effervescent tablets, oral solutions and suppositories for children. The attending physician typically determines which dosage form is suitable for the treatment.

Novaminsulfon is often used to relieve pain symptoms Herniated discs to alleviate. High fever can be lowered well by Novaminsulfon. Also at Joint pain through overload, in case of pain through a so-called Lumbago (Lumbago, acute lumbar syndrome) or due to sciatica, Novaminsulfon can be used. Further areas of application for Novaminsulfon are Measles disease, Meningitis (meningitis), ankylosing spondylitis (Ankylosing spondylitis) and Glandular Pfeiffer fever.

For severe to very severe pain requiring the use of opioid pain relievers (such as. Morphine) is not yet displayed, for example by Bruises, a headache, Toothache, stomach pain, Muscle aches or Back pain Novaminsulfon is also very effective.


Novaminsulfon is one of the non-acidic fever-lowering pain relievers from the group of non-opioid pain relievers. The mechanism of action for the active ingredient Metamizole is not yet fully clarified. It is believed to be on central nervous system (Spinal cord and brain) attacks, but also affects the rest of the body tissue.

Novaminsulfon seems to inhibit the transmission of pain from the location of the pain to the brain (location of pain perception). This pain mediation goes through certain tissue hormones, the so-called Prostaglandins. These prostaglandins are inflammatory messenger substances that are involved in the sensation of pain. Inhibiting the prostaglandins by Novaminsulfon leads to pain relief by reducing the sensitivity of the pain receptors in the tissue (analgesia). Since the active ingredient of Novaminsulfon also affects the pain-conducting nerve tracts in the brain and spinal cord, it also has a dampening effect on pain perception. In addition to pain relief, Novaminsulfon also has a muscle-relaxing or antispasmodic effect. Further mechanisms of action are suspected and discussed.

The effects of metamizole are similar to those of the acidic non-steroidal Anti-inflammatory drugs (so-called NSAIDs, e.g. Acetylsalicylic acid, Ibupforums). However, since metamizole is a non-acidic active ingredient, it does not or hardly accumulates in inflamed tissue and therefore does not have an anti-inflammatory effect (anti-inflammatory) in contrast to the acidic NSAIDs.


The Dosage and duration of use for Novaminsulfon is determined by the doctor depending on the severity of the pain or the level of the Fever set. The maximum daily dose is around 5 grams Novaminsulfon per day. In the elderly, in people with impaired kidney function or in poor general condition, the doctor will advise you decreased dosage prescribe.

After a single use of Novaminsulfon, the symptoms should have improved after a few hours.If this is not the case, the single dose can be taken several times throughout the day after consulting your doctor. The maximum daily dose should in no case exceeded and should never be given all at once.

The duration of use of Novaminsulfon depends on the type of complaint or the duration of the illness and is determined by the attending physician.

Side effects

Occasionally, allergic rashes or a drop in blood pressure may occur when using Novaminsulfon. Rarely, there are blotchy pimples or a lack of white blood cells (Leukocytes) on. Very rare side effects of Novaminsulfon are:

  • Pain reliever asthma
  • severe skin reactions (e.g. Stevens-Johnson syndrome, Lyell syndrome)
  • Circulatory shock with impaired consciousness
  • Protein in the urine
  • Urinary obstruction
  • Deterioration of kidney function
  • Urinary deficiency
  • mental disorders such as fear, excitement, delusions, depression

A life-threatening hematopoietic disorder (called agranulocytosis) and a lack of blood platelets (Thrombocytopenia) come. Agranulocytosis begins unspecifically with a disturbance of the general condition and fever, later mucosal ulcers, skin necrosis and localized lymphomas appear.The blood count should be checked regularly, especially when using Novaminsulfon for a longer period of time. If a fever occurs while using Novaminsulfon, the treatment should be stopped immediately and a doctor should be consulted. However, the risk of life-threatening agranulocytosis when using Novaminsulfon appears to be very low.

In the recommended dose ranges, there is no known impairment of the ability to concentrate and react, however, an impairment should be taken into account, especially with higher doses, which is why the use of machines, driving vehicles and other dangerous activities should be avoided.

Read more about this: Stevens Johnson Syndrome

When should Novaminsulfon not be used?

Novaminsulfon should not be used if one Hypersensitivity against the active ingredient Metamizole or similar substances. Likewise if a Intolerance to other pain relievers (non-opioid pain relievers, non-steroidal pain relievers) in the form of allergic reactions consists. With disorders of the bone marrow function, with diseases of the blood-forming system and with certain liver function disorders (e.g. acute hepatic porphyria) the use of Novaminsulfon is not indicated.

Particular care should be taken when administering Novaminsulfon allergic bronchial asthma, chronic hives, Kidney and liver dysfunction, high fever, serious injuries to the Coronary arteries, Cerebral vessels or after stroke and in people with low blood pressure or unstable circulation. In this case, Novaminsulfon should only be prescribed after careful medical risk-benefit assessment.

There may be medicinal products with which an interaction occurs during treatment with Novaminsulfon. In principle, it is advisable to discuss any other medication that has already been used with the attending physician before starting therapy with a new medication in order to rule out complications due to interactions.

Novaminsulfon in children

The novaminsulfon solution is injected into the muscle tissue of children who are older than 3 months.

The application of Novaminsulfon in children is specified differently for the individual dosage forms depending on the manufacturer. The restrictions can relate to the age, but also to the body weight of the child. The special warnings for each drug must therefore be observed.

In general, Novaminsulfon is found in Tablet form not for children under ten years is allowed. As Suppositories is a gift from 300 milligrams Metamizole to children over four yearse and down 1000 milligrams Metamizole to adolescents from 15 years authorized.

In newborns and infants under three months or under five kilograms Body weight, the use of Novaminsulfon is not permitted because the tolerance of the active ingredient has not been adequately researched in this age group.

For older children, Novaminsulfon is available in Teardrop shape to disposal.

The injection a Novaminsulfonlösung is allowed in a child that older than three months is, exclusively in that Muscle tissue (intramuscularly), an injection into the vein (intravenous) is not indicated.

Novaminsulfon during pregnancy and breastfeeding

Novaminsulfon is often given in tablet form.

There have been few meaningful studies to date on the tolerability of Novaminsulfon during one pregnancy, because too few pregnant women with the Active ingredient metamizole treated in order to be able to reliably assess the tolerance.
Basically, metamizole can be through the Plaster cake (placenta) get to the child. In animal experiments there was no damage to the unborn child, but it is recommended not to use Novaminsulfon at all in the first and third trimester of pregnancy. In the second trimester of pregnancy, the drug should only be used after strict medical benefit-risk assessment administered. The active ingredient metamizole inhibits the body's own production of the Tissue hormones prostaglandinswhich can lead to an undersupply of blood in the unborn child and a blood clotting disorder Complications in the birth could cause.

During treatment with Novaminsulfon and for at least 48 hours after its last use, breastfeeding must not be carried out, as the active ingredient metamizole and its metabolic products are in the Breast milk reach. (See also Medication during breastfeeding)